Genoscreen   Report issue

For profit Phase 3
Founded: Lille France (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2019
NCT03662022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Genoscreen

Active Ingredients

Drugs in Phase 3 Trials (1)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leprosy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1